BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 15454681)

  • 1. Use of the laboratory rat as a model in endocrine disruptor screening and testing.
    Gray LE; Wilson V; Noriega N; Lambright C; Furr J; Stoker TE; Laws SC; Goldman J; Cooper RL; Foster PM
    ILAR J; 2004; 45(4):425-37. PubMed ID: 15454681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Xenoendocrine disrupters-tiered screening and testing: filling key data gaps.
    Gray LE; Ostby J; Wilson V; Lambright C; Bobseine K; Hartig P; Hotchkiss A; Wolf C; Furr J; Price M; Parks L; Cooper RL; Stoker TE; Laws SC; Degitz SJ; Jensen KM; Kahl MD; Korte JJ; Makynen EA; Tietge JE; Ankley GT
    Toxicology; 2002 Dec; 181-182():371-82. PubMed ID: 12505339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selecting appropriate animal models and experimental designs for endocrine disruptor research and testing studies.
    Stokes WS
    ILAR J; 2004; 45(4):387-93. PubMed ID: 15454677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uncertainties for endocrine disrupters: our view on progress.
    Daston GP; Cook JC; Kavlock RJ
    Toxicol Sci; 2003 Aug; 74(2):245-52. PubMed ID: 12730617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro models in endocrine disruptor screening.
    Charles GD
    ILAR J; 2004; 45(4):494-501. PubMed ID: 15454688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors considered in using birds for evaluating endocrine-disrupting chemicals.
    Touart LW
    ILAR J; 2004; 45(4):462-8. PubMed ID: 15454685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small fish models for identifying and assessing the effects of endocrine-disrupting chemicals.
    Ankley GT; Johnson RD
    ILAR J; 2004; 45(4):469-83. PubMed ID: 15454686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use and role of invertebrate models in endocrine disruptor research and testing.
    deFur PL
    ILAR J; 2004; 45(4):484-93. PubMed ID: 15454687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tiered screening and testing strategy for xenoestrogens and antiandrogens.
    Gray LE
    Toxicol Lett; 1998 Dec; 102-103():677-80. PubMed ID: 10022334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-species conservation of endocrine pathways: a critical analysis of tier 1 fish and rat screening assays with 12 model chemicals.
    Ankley GT; Gray LE
    Environ Toxicol Chem; 2013 Apr; 32(5):1084-7. PubMed ID: 23401061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Key learnings from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 in vitro assays.
    LeBaron MJ; Coady KK; O'Connor JC; Nabb DL; Markell LK; Snajdr S; Sue Marty M
    Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):23-42. PubMed ID: 24515815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Tier I screening approaches for detecting endocrine-active compounds (EACs).
    O'Connor JC; Cook JC; Marty MS; Davis LG; Kaplan AM; Carney EW
    Crit Rev Toxicol; 2002; 32(6):521-49. PubMed ID: 12487364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Key lessons from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 male and female pubertal assays.
    Stump DG; O'Connor JC; Lewis JM; Marty MS
    Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):43-62. PubMed ID: 24510766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening chemicals for thyroid-disrupting activity: A critical comparison of mammalian and amphibian models.
    Pickford DB
    Crit Rev Toxicol; 2010 Nov; 40(10):845-92. PubMed ID: 20684730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine-disrupting chemicals: prepubertal exposures and effects on sexual maturation and thyroid function in the male rat. A focus on the EDSTAC recommendations. Endocrine Disrupter Screening and Testing Advisory Committee.
    Stoker TE; Parks LG; Gray LE; Cooper RL
    Crit Rev Toxicol; 2000 Mar; 30(2):197-252. PubMed ID: 10759431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Commentary: setting aside tradition when dealing with endocrine disruptors.
    Colborn T
    ILAR J; 2004; 45(4):394-400. PubMed ID: 15454678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use and acceptance of Other Scientifically Relevant Information (OSRI) in the U.S. Environmental Protection Agency (EPA) Endocrine Disruptor Screening Program.
    Bishop PL; Willett CE
    Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):3-22. PubMed ID: 24151143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Animal models and studies of in utero endocrine disruptor effects.
    Vandenbergh JG
    ILAR J; 2004; 45(4):438-42. PubMed ID: 15454682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approaches to the assessment of toxicity data with endpoints related to endocrine disruption.
    Harvey PW; Johnson I
    J Appl Toxicol; 2002; 22(4):241-7. PubMed ID: 12210541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a Tier I screening battery for detecting endocrine-active compounds (EACs) using the positive controls testosterone, coumestrol, progesterone, and RU486.
    O'Connor JC; Davis LG; Frame SR; Cook JC
    Toxicol Sci; 2000 Apr; 54(2):338-54. PubMed ID: 10774816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.